Earnings ·
Starling Oncology reported second quarter 2026 financial results, posting consolidated revenue of $161.3 million, a…
DFPHStarling Oncology, Inc.
Starling Oncology reported second quarter 2026 financial results, posting consolidated revenue of $161.3 million, a 34.6% increase from the prior year period. Gross profit rose 55.2% to $27.2 million, while net loss narrowed to $9.8 million compared to $17.0 million previously. Adjusted EBITDA turned positive at $229 thousand, up from a $4.1 million loss. The company raised its full-year 2026 revenue guidance to $650–$670 million and adjusted EBITDA guidance to $2–$7 million. Operational highlights include record specialty pharmacy fills driving a 58% year-over-year revenue increase in that segment, the addition of approximately 230,000 capitated lives through an exclusivity agreement in California, and new delegated contracts in Nevada and Oregon. Starling Oncology operates as a value-based community oncology group providing specialized cancer care.